The TARGET (Transforming Antibiotic R&D with Generative AI to stop Emerging Threats) Project is enabling Phare Bio to rapidly scale and optimize its generative AI discovery platform to thwart the ...

CHICAGO--(BUSINESS WIRE)--Massive Bio, a global company specializing in AI-powered clinical trial matching and oncology data solutions, is participating in the 2025 American Society of Clinical ...

Massive Bio, the global leader in AI-driven clinical trial matching for cancer patients, and Just Worldwide, a leading global ...

Just Worldwide will utilise its engagement infrastructure to increase awareness of Massive Bio's clinical trials.

Amazon Web Services (AWS) announced this Tuesday the launch of its AI bio tool, Amazon Bio Discovery, to accelerate the early-stage process of drug discovery in the pharmaceutical industry. The ...

The large AI player is paying $400 million for the tiny startup, signaling a potential shift in how tech is approaching opportunities in drug development.

Paris-based Spore.Bio, a startup that developed an artificial intelligence-driven method for detecting pathogens, said today it has raised $23 million in early-stage funding to reinvent microbiology ...

OpenAI is expanding its efforts to contain emerging risks posed by artificial intelligence, backing a new biotech spinoff aimed at stopping malicious actors from using advanced models to create ...

The South Korean multinational corporation has made a significant investment in advanced technologies as part of its commitment to delivering long-term value for its shareholders and consumers. For ...